Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks HS patient happiness on cosentyx

NCT ID NCT06785779

Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study surveys 77 adults with moderate to severe hidradenitis suppurativa (HS) in Saudi Arabia who are starting the medication Cosentyx (secukinumab). Researchers will ask patients about their treatment satisfaction and quality of life after 24 weeks. The goal is to understand how convenient, effective, and safe patients feel the treatment is in real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 77 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who are newly initiated on Secukinumab as per locally approved labels and routine clinical practice will be enrolled over a period of 6 months and followed up for 24 weeks to assess study outcomes

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or Female adult patients ≥18 years of age at the time of data collection. 2. Patient with a confirmed diagnosis of active moderate to severe HS. 3. Secukinumab naive patients (first dose to coincide within one month of the signature of the informed consent) as per locally approved label. 4. Patients can be using antibiotics or have undergone surgery as per routine clinical practice. 5. Patients agree to sign an informed consent form (ICF) to be able to complete the questionnaires. Exclusion Criteria: 1. Patients not fulfilling any of the above-mentioned inclusion criteria. 2. Patient's refusal to be included in the study or refusal to sign the ICF. 3. A history of off-label indication uses of biological treatment or JAK inhibitor.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa (HS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa (HS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Riyadh, SAU, 11525, Saudi Arabia

  • Novartis Investigative Site

    RECRUITING

    Jeddah, 21391, Saudi Arabia

  • Novartis Investigative Site

    RECRUITING

    Jeddah, 23311, Saudi Arabia

  • Novartis Investigative Site

    RECRUITING

    Riyadh, 11211, Saudi Arabia

More trials for these conditions

Other studies related to the condition(s) this trial covers.